About Us
At My Intelligent Machines, we are helping life scientists harness the power of human and artificial intelligence to push the boundaries of drug development.
Seventy percent of phase II and III clinical trials fail because patients with the same disease respond differently to treatments. This costs the biopharma industry more than $20B in losses annually. The cost of human life is even greater.
MIMs is a software-as-a-service (SaaS) company with an augmented-intelligence platform leveraging systems biology, distributed computing, and machine learning to unleash the power of reverse translational research. We are changing the research paradigm for endotype characterization, target and indication prioritization, and target and biomarker discovery, in oncology, immune-related disorders, infectious diseases, and more.
MIMs’ transformational software solutions are made possible by an inclusive team of remarkable and diverse humans – leaders of today and tomorrow in their respective fields. Together, we have brought a machine to life. Our love of science knows no bounds. Our plans are daring. Our future goals are lofty.
Our Product
Reduce costs, time, and failure rates associated with your clinical trials
MIMs' Platform
MIMs’ platform integrates our MIMsight Knowledge Base—which combines billions of data points and other information extracted from scientific literature, public databases, and multi-omic and clinical patient data-and our proprietary GI2 (Genetic Interaction Graph Inference) algorithm inferring genetic interactions within patient tumours and immune systems. These vivid human cartographies of individual patients deliver previously unimagined levels of precise insight used to classify patients into subgroups, identify their molecular and clinical characteristics, predict their response to new therapies, and identify powerful therapeutic targets and biomarkers.
With MIMs’ SaaS product for indication prioritization and biomarker discovery in oncology, you and your team can:
1. Access scientific insights to support strategic decisions on indication prioritization at the pre-clinical stage
2. Increase the success rate of clinical trials for new targeted and immune therapies
3. Explore new potent combined therapies
4. Accelerate early high-value biomarkers to accelerate companion test development
Team
Our co-founders combine 50 years of cumulated experience in Integrative Genomics, Bioinformatics and Artificial Intelligence
Sarah Jenna
Cofounder & CEO
Sarah obtained her Ph.D. degree in cell biology and microbiology in University Aix-Marseille in France in 1998 and a Junior Canadian research Chair in Integrative Genomics and Cell signaling at UQAM in 2006 (The IGCS Lab). As the co-founder and CEO of MIMs Inc., she translates this expertise to provide MIMs with state-of-the-art integrative genomics abilities and attention to specific needs of biologist users.
Mickaël Camus
Cofounder & CTO
Since 2001, Mickaël worked on various industrial projects concerning autonomous systems and unsupervised learning like a mission management System for uninhabited air vehicles for the european defence and an autonomous satellite constellation simulator for the european space agency concerning the Galileo project. During his Ph.D. Thesis from 2003 to 2007 at LIP6 from P6 & CNRS, Mickaël developed a system based on an ontology of making self-assessment decisions, that allows to generate models in real-time thanks to a massive multi-agent system. This discovery is as a master algorithm to control machines at a knowledge level (A. Newell). Lab: Mimetics Labs
Abdoulaye Baniré Diallo
Cofounder & CSO
Abdoulaye is fascinated by the usability and efficiency of bioinformatics services to solve biological questions and transform biologist main needs into accessible services. As director of the bioinfo lab at UQAM, he leads the development of more than 10 applications in bioinformatics including workflows, machine learning methods, ontologies and knowledge management of biological data. Abdoulaye has a Ph.D. in computer science (option bioinformatics) from the McGill University. He is a former research associate at the BroadInstitute of MIT and Harvard and postdoctoral scholar at the Computer Science and artificial intelligence Laboratory of MIT.
Meet the team
MIMs is a dynamic tech company with an exceptional culture that embraces diversity and inclusion. We are currently one of the very few tech companies to have reached gender balance
My Intelligent Machines
Sign up to receive our newsletters!